Antiandrogen withdrawal syndrome with nilutamide
Related Experiment Video
Updated: Oct 3, 2026

Murine Prostate Micro-dissection and Surgical Castration
Published on: May 11, 2016
S D Huan1, R G Gerridzen, J C Yau
1Division of Medical Oncology, Ottawa Regional Cancer Centre, Ontario, Canada.
Abstract:
Antiandrogens are combined with medical or surgical castration to achieve total androgen blockade in metastatic prostate cancer. Discontinuation of antiandrogens at disease progression has been associated with prostate-specific antigen (PSA) decrease, symptom improvement, and occasionally objective tumor regression. Two cases of metastatic prostate cancer demonstrating decrease in PSA of 92% and 56% on discontinuation of nilutamide therapy are reported. Improvement in urinary symptoms, bone pain and, in one, disappearance of para-aortic lymphadenopathy paralleled the PSA decrease. The duration of the withdrawal response of 6 months was comparable to those reported with discontinuation of flutamide.
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome II : Assessment and Medical Management

